Clinical trials: Interleukin
Plaque Psoriasis
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by…
- Trial name
- STEPin (NCT03020199)
- Testing
- Secukinumab, nb-UVB
- Where
- 44 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 196 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)
Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory…
- Trial name
- NCT01936844
- Testing
- Anakinra (high dose), Anakinra (standard dose)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Psoriatic Arthritis
Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
This study is designed as a proof of concept of AIN457 in patients with psoriatic arthritis. The study will address the evaluation of the efficacy at 6 and up to 24 weeks after two doses of AIN457 10 mg/kg administered three…
- Trial name
- NCT00809614
- Testing
- AIN457
- Where
- 10 sites in Germany, Netherlands and 1 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
The overall goal of this study is to understand biological responses related to dupilumab treatment among severe asthma patients. Not all asthma is the same, and characteristics of asthma vary from person to person.
- Trial name
- NCT05036733
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Nasal Polyps, Aspirin-exacerbated Respiratory Disease
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant…
- Trial name
- RECAP-5 (NCT05672030)
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
HIV Infections
Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
This study will examine whether interleukin-2 (IL-2) given before the interruption of antiretroviral (ARV) treatment could significantly extend the period of time that a patient is temporarily not taking ARV treatment and also…
- Trial name
- ILIADE (NCT00071890)
- Testing
- Interleukin 2, HAART, Treatment interruption
- Where
- 2 sites in United States, France
- Volunteers
- 148 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acneiform Eruptions
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
Efficacy and Safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (EGFRi)/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor (MEKi)-associated acneiform…
- Trial name
- NCT04697069
- Testing
- Imsidolimab
- Where
- 18 sites in United States, Czechia and 3 more
- Volunteers
- 4 people
- Sponsor
- Vanda Pharmaceuticals
Ichthyosis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
- Trial name
- NCT04697056
- Testing
- Imsidolimab
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- Vanda Pharmaceuticals
Metastatic Solid Tumors, Treatment-Refractory Cancers
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
Background: The drug Interleukin-15 (IL-15) activates the immune system. The drugs nivolumab and ipilimumab unblock immune cells.
- Trial name
- NCT03388632
- Testing
- rhIL-15, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Celiac Disease
A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
This study is designed to evaluate the efficacy and safety of AMG 714 for the attenuation of the effects of gluten exposure in adult patients with celiac disease during a gluten challenge.
- Trial name
- NCT02637141
- Testing
- AMG 714, Gluten Challenge
- Where
- 3 sites in Finland
- Volunteers
- 64 people
- Sponsor
- Amgen
Prostate Cancer
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate…
- Trial name
- NCT02555397
- Testing
- Ad5-yCD/mutTKSR39rep-hIL12
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
B-cell Non-Hodgkin Lymphoma
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
This dose-escalation study is designed for determining the safety, tolerability, pharmacokinetics (PK), biological, and clinical activity of DI-Leu16-IL2 administered to participants with cluster of differentiation 20 (CD20)…
- Trial name
- DI-Leu16-IL2 (NCT01874288)
- Testing
- DI-Leu16-IL2
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Alopexx Oncology, LLC
Breast Cancer
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib.
- Trial name
- NCT05966584
- Testing
- Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib)
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
This phase I/II trial studies the side effects and best dose of entinostat when given together with aldesleukin and to see how well this works in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01038778
- Testing
- Aldesleukin, Computed Tomography, Entinostat
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Psoriatic Arthritis
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
This study is designed as an extension study to the proof-of-concept trial CAIN457A2206 in patients with psoriatic arthritis and aims to provide continuous treatment with AIN457 for patients in the core trial, to obtain safety…
- Trial name
- NCT01169844
- Testing
- AIN457A, Other
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis
This study is designed as an extension study to the proof-of-concept trial CAIN457A2209 in patients with moderate to severe ankylosing spondylitis and aims to provide continuous treatment with AIN457 for patients in the core…
- Trial name
- NCT01109940
- Testing
- AIN457A
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis
Mechanistic Inflammatory Sub-study Embedded Within the Albumin vs Balanced Crystalloid Trial
MIS-ABC Sepsis is a sub-study looking to understand how the immune response in patients with infection changes during the early stages of the illness, as well as after intravenous fluid treatment.
- Trial name
- MIS-ABC Sepsis (NCT04963569)
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University of Edinburgh
Asthma
A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma
This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.
- Trial name
- NCT01479595
- Testing
- QBX258
- Where
- 20 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Carcinoma
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
Background: People with cancer can have a weak immune system as a result of the cancer itself, or from prior treatments. Still, treatments that stimulate the immune system have been shown to be effective against a number of…
- Trial name
- NCT01572493
- Testing
- rh IL-15 (10 DAYS), rh IL-15 (5 DAYS)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Colitis, Ulcerative
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.
- Trial name
- INSTRUCT-UC (NCT04677179)
- Testing
- LY3471851
- Where
- 116 sites in United States, Argentina and 20 more
- Volunteers
- 81 people
- Sponsor
- Nektar Therapeutics